Prolonged exposure of cultured hippocampal slices to CX614 [2H,3H,6aH-pyrrolidino[2Љ,1Љ-3Ј,2Ј]1,3-oxazino[6Ј,5Ј-5,4]-benzo[e]1,4-dioxan 10-one], a positive ␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor (AMPAr) modulator, decreases receptor response to synaptic stimulation, an effect that could reflect reduced receptor expression. The present study investigates this down-regulation and its underlying mechanisms using cultured rat hippocampal slices. Chronic treatment with CX614 gradually reduced levels of glutamate receptor (GluR)1 and GluR2/3 AMPAr subunits and of their anchoring proteins synapse-associated protein 97 (SAP97) and glutamate receptor interacting protein 1 (GRIP1) through 48 h. Decline in SAP97 and GRIP1 levels was associated with increased abundance of lower molecular weight bands, suggesting degradation of these proteins. CX614 effects were partially reversible after drug removal. GluR1 and GluR2/3 down-regulation and their slow recovery were associated with similar changes in SAP97 and GRIP1 levels. Treatment with CX614 for 48 h significantly reduced AMPAr mRNA levels in hippocampus, whereas 8-h exposure did not. Blockade of ionotropic glutamate receptors prevented CX614-induced decrease in AMPAr subunits and mRNA, with regional selectivity, although an AMPAr blocker was more efficacious than an N-methyl-D-aspartate receptor blocker. Blockade of calpain activity reduced CX614-induced degradation of SAP97 and GRIP1 and prevented decreases in AMPAr subunit but not mRNA levels. Treatment with CX614 alone or in combination with glutamate receptor blockers or calpain inhibitor III did not modify lactate dehydrogenase release into culture medium, implying the absence of cell toxicity. We conclude that CX614-induced AMPAr protein loss is primarily mediated by AMPAr activation and involves calpain-dependent proteolysis of SAP97 and GRIP1. CX614-induced suppression of AMPAr gene expression is, however, calpain-independent, and all these effects are not associated with cell damage.
. AMPAr interactions with distinct scaffolding PDZ proteins regulate the intracellular trafficking and localization of the receptors. For instance, SAP97 and PSD-95 are important for targeting the receptors to synaptic membranes, protein interacting with C kinase 1 is involved in receptor internalization, and SAP97 and GRIP1 contribute to the stabilization of receptor subunits and to receptor trafficking between different subcellular compartments (Iwakura et al., 2001; Jourdi et al., 2003; Ahmadian et al., 2004; Collingridge et al., 2004 , and references therein). Moreover, treatment of neurons with glutamate, NMDA, or brain-derived neurotrophic factor (BDNF) results in translocation of AMPAr to the cell surface via a mechanism involving interaction of the AMPAr subunit GluR2 with the N-ethylmaleimide sensitive factor (Broutman and Baudry, 2001; Braithwaite et al., 2002; Narisawa-Saito et al., 2002; Collingridge et al., 2004) .
CX614 belongs to the benzamide family of positive AMPA receptor modulators (or ampakines). These drugs up-regulate AMPAr-mediated electrophysiological responses to glutamate, increase miniature excitatory postsynaptic current frequency and amplitude, and facilitate LTP (Arai et al., , 2002a Suppiramaniam et al., 2001) . CX614 increases the amplitude of AMPAr-mediated currents, prolongs the "open-channel" state of the receptor, and increases the frequency and amplitude of miniature excitatory postsynaptic potential. However, prolonged exposure to CX614 results in desensitization and/or rundown of the receptor response . Such AMPAr down-regulation could possibly reflect enhanced AMPAr internalization and/or removal of the receptors from the synaptic pool.
Calpain is a Ca 2ϩ -dependent protease present in the synaptic compartment. Its activation is required for the induction of LTP and occurs after incubation of neurons with NMDA, glutamate, and theta burst stimulation (Oliver et al., 1989; Bednarski et al., 1995; Muller et al., 1995; Vanderklish et al., 1996) . Conversely, suppression of calpain expression or activity blocks LTP (Oliver et al., 1989; Denny et al., 1990; Bednarski et al., 1995; Vanderklish et al., 1996) . Moreover, calpain truncates the C-terminal domains of several AMPA and NMDA receptor subunits, as well as PSD-95 and GRIP1, members of the PDZ family of proteins (Lu et al., 2000 , and the cytoskeletal protein spectrin (Baudry and Lynch, 1981) . In a recent report, we showed that prolonged incubation of cultured hippocampal slices with CX614 resulted in calpain activation and calpain-mediated proteolysis of spectrin (Jourdi et al., 2005) . Together, these studies indicate that calpain plays a critical role in the reorganization of glutamatergic postsynaptic compartment after a number of stimuli, resulting in increased calcium concentrations in postsynaptic structures. They also suggest that calpain-mediated proteolysis of AMPAr-associated PDZ proteins might be involved in down-regulation of AMPAr. The possibility that prolonged exposure of cultured hippocampal slices to CX614 could lead to the destabilization of AMPAr complexes and the elimination of the receptor subunits was addressed in the present study.
Materials and Methods
Hippocampal Slice Cultures. Ten-to 12-day-old rat pups were obtained from The Jackson Laboratory (Bar Harbor, ME) and used to prepare hippocampal slice cultures as described previously (Jourdi et al., 2005) . Briefly, animals were decapitated, and the brains were dissected, trimmed, and 400-m-thick hippocampal slices were cut using a McIllwain tissue slicer (Fotodyne Inc., New Berlin, WI). Slices were explanted onto Millipore insert membranes, placed in six-well culture plates, and fed with regular slice culture medium (50% basal Eagle's medium, 25% Earl's balanced salt solution, 136 mM sodium chloride, 2 mM calcium chloride, 2.5 mM magnesium sulfate, 5 mM sodium bicarbonate, 3 mM glutamine, 40 mM glucose, 0.5 mM ascorbic acid, 20 mM HEPES buffer, 1 mg/l insulin, 5 U/ml penicillin, and 5 mg/l streptomycin; pH 7.3) supplemented with 5% fetal bovine serum and 5% horse serum. Slices were kept in culture for 2 weeks and fed with 1 ml of fresh medium every other day. Slices were then treated with CX614, glutamate receptor antagonists, or calpain inhibitor III, at the following concentrations: CX614, 50 M; AP-5, 100 M; CNQX, 50 M; and calpain inhibitor III, 10 M. At the indicated times after treatment initiation, slices were collected and processed for immunoblotting, immunocytochemistry, or in situ hybridization as described below. The AMPAr-positive modulator CX614 was generously provided by Cortex Pharmaceuticals (Irvine, CA). AP-5, CNQX, and calpain inhibitor III were purchased from Sigma-Aldrich (St. Louis, MO).
Immunocytochemistry. Slices were washed twice in cold phosphate-buffered saline, fixed overnight with 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4, at 4°C, postfixed and cryoprotected overnight at 4°C in 4% paraformaldehyde in 0.1 M phosphate buffer (PB) supplemented with 20% sucrose, and then sectioned using a freezing microtome. Free-floating sections (25 m) were washed in 0.1 M PB and blocked for 1 h with 10% horse or goat serum in 0.1 M PB (ϩ 1% Triton X-100) and then incubated with the primary antibody (1:1000) overnight at 4°C in 5% horse serum. Tissue was then washed in 0.1 M PB and incubated with the biotinylated secondary antibody (diluted 1:400) in 5% horse or goat serum/0.1 M PB for 2 h at room temperature. After washes in 0.1 M PB, the tissue was incubated in avidin biotin complex working solution (ABC Elite Vectastain kit; Vector Laboratories, Burlingame, CA) and then reacted using the peroxidase substrate SK-4100 Vector kit (Vector Laboratories) with 3,3Ј-diaminobenzidine as chromagen. After final washes in 0.1 M PB, the sections were mounted onto Superfrost Plus slides (Fisher Scientific, Tustin, CA), air-dried, dehydrated with ethanol, cleared with Americlear (Fisher Scientific, Tustin, CA), and coverslipped. Stained sections were examined using a Zeiss Axioskop2 microscope fitted with an AxioCam camera and operated with AxioVision 3.1.2.1 software (Carl Zeiss, Thornwood, NY) .
Polyacrylamide Gel Electrophoresis and Western Blotting. Slices were collected into cold homogenizing buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, 10 mM NaF, and 1 mM Na 3 VO 4 ; all from SigmaAldrich, St. Louis, MO) supplemented with protease inhibitor cocktail (Sigma-Aldrich) [2.08 mM 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride, 1.6 M aprotinin, 40 M leupeptin, 80 M bestatin, 30 M pepstatin A, and 28 M trans-3-carboxyoxirane-2-carbonyl-L-leucylagmatine], sonicated five times using a Virsonic cell disruptor set at 50% for 4-to 7-s intervals, and protein concentrations were determined. Equal amounts (20 -40 g) of sample proteins were separated according to their molecular weight on 8 to 10% SDS polyacrylamide gels and transferred onto nylon/polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA). After transfer, membranes were blocked with 5% milk in 1ϫ TBS-T (137 mM NaCl, 20 mM Tris base, and 0.1% Tween 20; pH 7.4) for 1.5 h. Membranes were probed with the primary antibody diluted with 5% milk (1: 1000) and incubated overnight at 4°C. Membranes were then washed with 1ϫ TBS-T and incubated with horseradish peroxidase-conjugated secondary antibodies (Amersham Biosciences Inc., Piscataway, NJ) in a 1:10,000 dilution with 1ϫ TBS-T for 1 h followed by washing in TBS-T. Membranes were exposed to enhanced chemiluminescence Western blotting detection reagent (Amersham Biosciences Inc.) for 2 min, placed in an autoradiography cassette, and exposed to Hyperfilm (Amersham Biosciences Inc.) for different jpet.aspetjournals.org lengths of time. All membranes were stripped and reprobed with anti-actin antibodies (Sigma-Aldrich) as loading controls. Intensities of immunoreactive bands were quantified by densitometry, normalized to actin content, and analyzed by Student's t test.
Antibodies. For Western blotting, the following primary antibodies were used at the indicated final concentrations: 0.1 g/ml monoclonal mouse anti-actin (Sigma-Aldrich), 0.5 g/ml polyclonal rabbit anti-GluR1 (Chemicon International, Temecula, CA), 0.5 g/ml polyclonal rabbit anti-GluR2/3 (Chemicon International), 0.5 g/ml polyclonal rabbit anti-NR1 (Chemicon International), 0.5 g/ml polyclonal rabbit anti-NR2A/B (Chemicon International), polyclonal rabbit anti-GRIP1 (Upstate Biotechnology, Chicago, IL), monoclonal mouse anti-SAP97 (StressGen Biotechnologies, Victoria, BC, Canada). Horseradish peroxidase-conjugated secondary antibodies were purchased from Amersham Biosciences Inc. and used at 1:10,000 dilution. For immunocytochemistry, the polyclonal anti-GluR1 and anti-GluR2/3 antibodies and a monoclonal mouse anti-GluR2 (Chemicon International) antibody were used. All antibodies were diluted to 5 to 10 g/ml. Secondary antibodies for immunocytochemistry were purchased from Vector Laboratories.
In Situ Hybridization. After drug treatments, cultures were washed twice with Tris-buffered saline and fixed overnight in cold fixative solution (4% paraformaldehyde solution in 0.1 M PB; pH 7.3). Cultures were kept in fixative at 4°C until sectioning at 25 m with a freezing microtome. Sections were mounted onto Superfrost Plus slides and processed for the in situ hybridization localization of GluR1 and GluR2 mRNAs using 35 S-labeled complementary RNA probes at a concentration of 1 ϫ 10 7 cpm/ml with hybridization incubation times of 16 to 20 h at 60°C as described previously (Lauterborn et al., 2000) . The GluR1 and GluR2 complementary RNAs were transcribed from BglI and BamHI digests of p59/2 and pRB14, respectively, and are complementary to 895 and 900 bases, respectively, of the 3Ј ends, including the noncoding region. After hybridization, the tissue was treated with RNase A (20 g/ml; 30 min; 45°C) and washed in descending concentrations (2ϫ-0.1ϫ) of saline sodium citrate buffer, 30 min each (1ϫ ϭ 0.15 M NaCl/0.015 M sodium citrate; pH 7.0). The tissue was air-dried and processed for Biomax film (Eastman Kodak, Rochester, NY) autoradiography with exposure times of 1 to 2 days. Hybridization densities within hippocampal CA1 and CA3b stratum pyramidale were measured from film autoradiograms, with labeling densities calibrated relative to film images of 14 C-labeled standards (American Radiolabeled Chemicals, St. Louis, MO) using the AIS imaging system (Imaging Research, St. Catherines, ON, Canada). For each field, significance of effect of treatment was determined by the two-way analysis of variance followed by planned post hoc analysis using Student-NewmanKeuls post hoc test for individual comparisons. Statistical analyses were conducted using Prism software (version 3; GraphPad Software, Inc., San Diego, CA), and the 95% confidence level was considered significant.
Lactate Dehydrogenase Activity. Lactate dehydrogenase (LDH) enzymatic activity in the culture medium was used to evaluate the extent of cellular damage produced in cultured slices subjected to the different treatments. Briefly, culture medium was collected after 8-or 48-h incubation of slices with CX614 alone, calpain inhibitor III alone, the glutamate receptor blockers AP-5 and CNQX, CX614 ϩ glutamate receptor blockers, CX614 ϩ calpain inhibitor III, and from untreated control cultures. Spectrophotometric determination was used to measure LDH activity by monitoring the rate at which the substrate pyruvate is reduced to lactate (Regan and Choi, 1994) . Reaction mixtures consisted of 600 l of potassium phosphate buffer (0.1 M; pH 7.5 at 25°C), 400 l of supernatant culture medium, and 500 l of sodium pyruvate solution (22.7 mM in 0.1 M phosphate buffer; pH 7.5). The absorbance was read at 340 nm at 30-s intervals for 3 min. All reagents were purchased from Sigma-Aldrich.
Results

Treatment of Cultured Hippocampal Slices with CX614 Induces a Gradual Loss of AMPAr Subunits.
Hippocampal slices obtained from postnatal day 10 rat pups were maintained in culture for 10 to 14 days. Previous studies by our laboratories indicated that treatment of cultures for 48 h with CX614 decreased AMPAr subunit mRNA and protein levels (Lauterborn et al., 2003) . To assess the time course of CX614 on AMPAr protein, cultured slices were incubated with 50 M CX614 for 0, 4, 8, 12, 24, and 48 h (Fig.  1 ). Significant decreases in GluR1 and GluR2/3 levels were observed after 4 h of incubation. There was a near linear decline in GluR1 and GluR2/3 subunits over time with CX614 treatment through 24 h (Fig. 1B) . The decrease in AMPAr subunit levels continued at a slower rate between 24 and 48 h of treatment. Probing the same samples with antibodies specific to the NMDA receptor subunits NR1 and NR2A/B did not show significant differences from control at any time point (Fig. 1C) ; levels of NR1 subunits were decreased by ϳ15%, whereas those of NR2A/B were increased by ϳ5% after 48-h treatment with CX614 ( Fig. 1D) . The results for GluR1 and GluR2/3 subunits were confirmed using immunohistochemistry; untreated control cultures and cultures treated with CX614 for 48 h were stained with the following AMPAr-specific antibodies: anti-C-terminal GluR1, anti-Cterminal GluR2/3, and anti-N-terminal GluR2 (Fig. 1E) . Overall, immunostaining with all three antibodies was decreased. In addition, with antibodies against the C-terminal domain of GluR1, intense staining of some cell bodies was observed, an effect reminiscent of what we previously observed after calcium treatment of tissue sections (Bi et al., 1998) .
Prolonged Treatment of Hippocampal Slices with CX614 Results in Degradation of AMPAr-Associated PDZ Proteins. AMPA receptor localization and trafficking in neurons are regulated by interactions of the receptors with several anchoring proteins, including SAP97 and GRIP1. Potential CX614-mediated degradation of SAP97 and GRIP1 could hinder trafficking of AMPAr to the cell membrane, destabilize the postsynaptic AMPAr compartment, and contribute to, or facilitate, CX614-induced loss of AMPAr subunits. To test for this possibility, levels of SAP97 and GRIP1 were assessed in hippocampal slices incubated for 48 h with or without 50 M CX614 ( Fig. 2A) . In Western blots, anti-SAP97 antibodies labeled three bands migrating at 140, 125, and 97 kDa, which were previously described as representing different SAP97 isoforms ( Fig. 2A, top) . A comparable decrease in levels of the three bands occurred after CX614 treatment; in this and subsequent figures, levels of the major SAP97 band at 97 kDa was used as a representation of overall changes in SAP97 protein levels. CX614 treatment for 48 h decreased SAP97 levels to 44 Ϯ 18% of control values (Fig. 2B) . Similarly, GRIP1 levels were decreased to 58 Ϯ 14% of control in CX614-treated samples (Fig. 2B) . These results were confirmed using immunocytochemistry; GRIP1 immunoreactivity was uniformly reduced in CX614-treated slices compared with untreated control slices (data not shown). After prolonged exposure of Western blots to film, bands corresponding to native SAP97 and GRIP1 proteins were saturated (Fig. 2C) . However, additional lower molecular weight bands became visible, and these were more in-tense in CX614-treated compared with control conditions (Fig. 2C) , suggesting that CX614 treatment resulted in proteolysis of the native proteins. Quantification of the intensity of these bands indicated that treatment of slices with CX614 increased levels of these fragments by 219 Ϯ 9% for SAP97 and by 178 Ϯ 9% for GRIP1 compared with untreated control slices (Fig. 2D) .
Parallel Effects of CX614 on AMPAr Subunits and SAP97 and GRIP1. Incubation of cultured hippocampal slices with CX614 induced a marked decline in AMPAr subunit levels within 8 h. To determine whether these effects of CX614 were reversible, cultures were treated with CX614 for 8 h and then transferred to control medium and maintained for various lengths of time (0, 4, 8, 12, 24 , and 48 h). In parallel, sister cultures were exposed continuously to CX614 for 48 h. Cultures were collected and levels of AMPAr subunits, SAP97, and GRIP1 were analyzed by Western blotting. As expected, treatment of cultures with CX614 for 8 h induced a significant decrease in levels of AMPAr subunits and SAP97 (Fig. 3) . Similarly, slices treated continuously with CX614 for 48 h exhibited a large decrease in levels of AMPAr subunits and of their partner PDZ proteins. Transfer of cultures to fresh CX614-free medium was not sufficient to immediately reverse the effects of the drug, as levels of AMPAr subunits, SAP97, and GRIP1 continued to decline for another 4 to 8 h. Levels of AMPAr subunits and of their partner PDZ proteins had slightly recovered by 24 h of drug washout. However, even after 48 h of incubation in the absence of CX614, levels of AMPAr subunits, SAP97, and GRIP1 did not completely return to control levels.
Effects of CNQX and AP-5 on CX614-Mediated Decreases in AMPAr Subunit and PDZ Protein Levels. To investigate whether activation of AMPA and NMDA receptors was involved in CX614-mediated down-regulation of AMPAr subunits and their PDZ partner proteins, control (DMSO vehicle) or CX614-treated hippocampal slice cultures were incubated with the NMDAr antagonist AP-5 (50 M) and the AMPAr antagonist CNQX (100 M). Cultured slices were treated with or without AP-5 ϩ CNQX for 30 min before the addition of 50 M CX614 and then further incubated for 48 h. Levels of AMPAr subunits, SAP97, and GRIP1 were determined by Western blotting (Fig. 4A) . Quantification of the blots (Fig. 4B ) demonstrated that treatment of cultures with CNQX ϩ AP-5 increased levels of GluR1 subunits without affecting levels of GluR2/3, SAP97, and GRIP1 (Fig. 4B) . Furthermore, combined treatment with CNQX ϩ AP-5 blocked the effects of CX614 on GluR1, GluR2/3, SAP97, and GRIP1 protein levels.
To assess whether CX614 effects on AMPAr and PDZ protein down-regulation involved activation of NMDAr and/or AMPAr, we incubated slices with CX614 alone, AP-5 alone, CNQX alone, CX614 ϩ AP-5 (50 M), or CX614 ϩ CNQX (100 M) (Fig. 4C) . The results indicated that although CNQX was more efficacious than AP-5, it did not completely block CX614-induced decrease in GluR1 and SAP97 (Fig. 4D) . Finally, treatment with AP-5 alone significantly reduced GluR1, GluR2/3, and GRIP1 levels compared with untreated control slices (DMSO vehicle) but had no effect on SAP97, whereas treatment with CNQX alone had no significant effects on GluR1, GluR2/3, and GRIP1 but significantly reduced SAP97 expression. CX614 on GluR1 and GluR2 mRNA levels (Fig. 5) . In a first set of experiments, cultured hippocampal slices were incubated under control conditions or with CX614, AP-5 ϩ CNQX, or CX614 together with AP-5 ϩ CNQX for 8 h. Although GluR1 mRNA levels showed a tendency to decrease in CX614-treated slices, no significant differences in GluR1 or GluR2 mRNA levels were observed under any conditions in CA1 and CA3 pyramidal cell layers at this time point (data not shown). In contrast, slices incubated for 48 h with CX614 exhibited a marked decrease in GluR1 and GluR2 mRNA levels in the pyramidal cell layer of both hippocampal subfields (Fig. 5) . Treatment with CNQX ϩ AP-5 alone for 48 h had opposite effects on GluR mRNA levels with modest increases in GluR1 (consistent with protein changes presented in Fig. 4 ) and small decreases in GluR2 mRNA levels: significant effects of treatment were reached for GluR1 and GluR2 mRNA levels in CA3 and CA1, respectively. Interestingly, treatment with CNQX ϩ AP-5 markedly reversed the effects of CX614 for both mRNAs only in CA3. Two-way ANOVA analysis revealed a significant reduction of CX614 effects by the blockers for GluR2 mRNA (p ϭ 0.0006) and a strong trend for GluR1 mRNA (p ϭ 0.0509). By contrast, in region CA1, CNQX ϩ AP-5 treatment did not block the CX614-induced decreases in GluR mRNA levels. Two-way ANOVA analysis revealed no significant reduction of CX614 effects by the blockers for both GluR1 (p ϭ 0.008) and GluR2 (p ϭ 0.0075) mRNAs in this field.
Effects of a Calpain Inhibitor on CX614-Induced Down-Regulation of AMPAr and Their Interacting PDZ Proteins. As mentioned above, treatment of cultures with CX614 increased the amount of small molecular weight bands that reacted with SAP97 and GRIP1 antibodies. We previously identified GRIP1 and PSD-95, another PDZ protein that shares a similar structure with SAP97 and that interacts with glutamate receptors, as substrates of the calcium-activated protease calpain (Lu et al., 2000 . Preliminary results showed that probing brain membrane fractions pretreated with Ca 2ϩ (2 mM and 30 min at 37°C, conditions that activate endogenous calpain) with anti-GRIP1 antibodies showed bands that migrated at the same level as those generated after treatment of cultured hippocampal slices with CX614 (data not shown). Moreover, we recently reported that CX614 treatment activates calpain and leads to the degradation of the cytoskeletal protein spectrin (Jourdi et al., 2005) . These results suggested that prolonged treatment with CX614 could result in calpainmediated SAP97 and GRIP1 degradation, thereby leading to AMPAr down-regulation by interfering with PDZ proteindependent stabilization and/or intracellular AMPAr trafficking. To test this hypothesis, we incubated cultured hippocampal slices with CX614 with or without calpain inhibitor III for 48 h. Western blot analysis indicated that calpain inhibitor III significantly reduced CX614-induced decreases in AMPAr subunits as well as decreases in the levels of their interacting PDZ proteins (Fig. 6) . Again, the results underscored the parallel effects of calpain inhibition on GluR1 and SAP97 and on GluR2/3 and GRIP1. In particular, calpain inhibitor III almost completely reversed the effect of CX614 on GRIP1 and GluR2/3.
We also tested whether calpain inhibitor III could block the effects of CX614 on the levels of GluR1 and GluR2 mRNA (Fig. 7) . Incubation of slices with calpain inhibitor III alone for 48 h had no significant effect on GluR1 and GluR2 mRNA levels in any subfield of hippocampus. However, unlike the protein effects, calpain inhibitor III had no significant effect on CX614-induced decreases in levels of GluR1 and GluR2 mRNAs. Two-way ANOVA indicated no significant effect of calpain inhibitor III on CX614-induced decrease in GluR mRNA levels in either hippocampal subfield.
CX614 Effects Are Not Due to Excitotoxicity. LDH activity has been widely used to assess the integrity of the cell membrane and as a measure of toxicity-induced cellular damage that could lead to cell death (Regan and Choi, 1994) . To investigate whether the marked decreases in levels and expression of AMPAr subunits and PDZ proteins after prolonged incubation of cultured hippocampal slices with CX614 jpet.aspetjournals.org could result from neuronal toxicity, we measured LDH activity in the culture medium from hippocampal slices treated with the AMPAr modulator under a variety of experimental conditions for 8 and 48 h (Fig. 8 ). There were no significant differences in LDH activity in cultures treated with CX614 alone, calpain inhibitor III alone, or CNQX ϩ AP-5 at either time point. Similarly, treatment of slices with combinations of CX614 and calpain inhibitor III, or CX614 and AP-5 ϩ CNQX did not modify LDH activity.
Discussion
Previous studies have shown that treatment with CX614 in cultured hippocampal slices over several hours increases AMPAr-mediated currents. However, with longer exposure intervals, CX614 decreases AMPAr currents, suggesting either decreased receptor responsiveness, increased receptor desensitization, or loss of AMPAr expression over time (Arai et al., , 2002a Lauterborn et al., 2000 Lauterborn et al., , 2003 Nagarajan et al., 2001) . The present data demonstrate that indeed there is a loss of AMPAr mRNA and protein expression after chronic CX614 treatment. Sustained CX614-induced increases in glutamatergic transmission could over time become toxic and such toxicity might provide an explanation for CX614-induced decrements in AMPAr-mediated currents. Our results reveal that despite its ability to down-regulate AMPAr protein levels and their mRNAs, CX614 did not increase LDH release, arguing against toxicity and implying uncompromised cell membrane integrity. Also, the present AMPAr immunocytochemical results and previous morphological evaluation of various hippocampal subfields in Nisslstained tissue sections did not reveal any signs of cell death in ampakine-treated slice cultures (Lauterborn et al., 2000) . In addition, CX614 is a potent inducer of the neuroprotective and survival-promoting neurotrophin BDNF (Lauterborn et al., 2000) .
Recently, we showed a gradual accumulation of CX614-induced calpain-mediated spectrin breakdown products that was completely blocked by calpain inhibitor III and by the AMPAr blocker CNQX but unaffected by the NMDAr blocker AP-5 (Jourdi et al., 2005) . In the present study, decreases in levels of AMPAr subunits and of their respective anchoring PDZ proteins were significant after 4 h of CX614 treatment and became greater with longer incubation intervals. Coadministration of AP-5 and CNQX completely blocked CX614 effects on AMPAr subunits and PDZ proteins. The effects of CX614 on AMPAr and PDZ proteins were partially reduced in the presence of CNQX alone, and AP-5 was less efficacious in blocking CX614 effects on AMPAr and PDZ proteins. Previous studies have demonstrated that NMDArs are tonically active in hippocampal slices (Sah et al., 1989) , and our results indicated that AP-5 partially reduced CX614 effects on SAP97 and GluR2/3. In addition, AP-5 significantly decreased CX614 effects on GRIP1 but not on GluR1. Together, our results argue against NMDArs being the principal source of increases in intracellular Ca 2ϩ needed for calpain activation with the manipulations described here. However, AMPArs are Na ϩ channels and are, by and large, impermeable to Ca 2ϩ ions (Lomeli et al., 1994; Jensen et al., 1998; Carlson et al., 2000; Iizuka et al., 2000; Krampfl et al., 2002; Kumar et al., 2002) . Interestingly, elevated intracellular Na ϩ levels can increase Ca 2ϩ release from intracellular stores (Hoyt et al., 1998; Zhang and Lipton 1999) , thus CX614-induced increases in AMPAr function and the resulting depolarization may contribute to increased intracellular levels of Ca 2ϩ . Pertinent to this, ryanodine receptors, which regulate intracellular Ca 2ϩ release, are also targets for calpain proteolysis (Shoshan-Barmatz et al., 1994) . Thus, CX614-dependent increases in AMPAr activity might enhance intracellular Ca 2ϩ concentrations and consequently activate calpain that then can truncate ryanodine receptors; this would exacerbate Ca 2ϩ release from intracellular stores and further enhance calpain-dependent degradation of AMPAr-interacting PDZ proteins and spectrin. Interestingly, calpain activation, ryanodine receptors, and the release of Ca 2ϩ from intracellular stores are tied to aspects of AMPAr function. Calpain activation is required for LTP induction (Vanderklish et al., 1996) , and recent studies of type 3 ryanodine receptors provide strong support for the involvement of intracellular Ca 2ϩ stores in calpain activation because deletion of this receptor impairs some forms of AMPAr-mediated synaptic plasticity, LTP, and spatial learning (Balschun et al., 1999; Shimuta et al., 2001) .
Our results clearly show that calpain activation is predominantly downstream from AMPAr and that it mediates CX614-induced AMPAr protein loss and degradation of PDZ proteins and spectrin (Jourdi et al., 2005) . In particular, calpain inhibition blocked CX614-induced decrease in PDZ protein levels and formation of PDZ protein degradation products, and it blocked CX614 effects on AMPAr subunits. In addition, down-regulation of individual AMPAr subunits and their recovery after CX614 washout were associated with similar changes in their interacting PDZ proteins. GRIP1 is implicated in GluR2 stabilization (Jourdi et al., 2003) , and GRIP1 truncation by calpain has been shown to decrease GRIP1-GluR2 association . Our data also indicate that SAP97, which is implicated in GluR1 intracellular trafficking, in its insertion in membranes, and in the stabilization of GluR1 protein (Jourdi et al., 2003; Collingridge et al., 2004) , is a calpain substrate as well.
Calpain activation leads to the truncation of GluR1 and GluR2 C-terminal domains (Bi et al., 1998) . Thus, a reduction in AMPAr subunits and/or a loss of their C-terminal epitopes could contribute to CX614-induced decreases in AMPAr immunoreactivities observed in this study. Although our immunostaining results cannot exclude truncation of AMPAr C-terminal domains from being responsible for lower levels of immunoreactivity, the results obtained with the anti-N-terminal GluR2 antibody strongly favor the loss of total protein expression with chronic exposure to CX614, at least for GluR2. In addition, truncation of GluR1 and GluR2 C-terminal domains (Bi et al., 1998) , and degradation of PDZ proteins and spectrin by calpain might dissociate AMPAr from the cytoskeleton, change their channel properties, and alter their rate of internalization.
AMPAr down-regulation generally involves dissociation from interactions with cytoskeletal and PDZ proteins and is followed by internalization and proteolysis (Ahmadian et al., 2004; Collingridge et al., 2004; Lee et al., 2004) . As such, prolonged application of CX614 is likely to cause destabilization and internalization of surface-bound receptors and reduced recycling to the synapse given the down-regulation of SAP97 and GRIP1 and their calpain-mediated degradation observed here. In fact, the interaction of AMPAr with the jpet.aspetjournals.org cytoskeleton and their internalization are highly regulated mechanisms involving several kinases and phosphatases (Iwakura et al., 2001; Rong et al., 2001; Ahmadian et al., 2004; Collingridge et al., 2004) . Future studies will investigate whether CX614 and other positive AMPAr modulators recruit distinct kinase pathways to regulate AMPAr surface expression. In addition, various manipulations can induce AMPAr internalization, including LTD or treatment with insulin. The type and duration of the inducing stimulus determine the fate of internalized AMPAr that can be either recycled to the synapse or targeted for terminal proteolysis (Iwakura et al., 2001; Ahmadian et al., 2004; Collingridge et al., 2004; . Future studies will investigate whether LTD-induced AMPAr internalization implicates calpain and whether CX614, and other positive AMPAr modulators, regulate AMPAr surface expression.
BDNF is important for AMPAr expression (Narisawa-Saito et al., 2002; Jourdi et al., 2003) , and chronic exposure of hippocampal slice cultures to CX614 initially leads to increases in BDNF mRNA and protein expression that are not maintained past 24 to 48 h. However, intermittent application of CX614 was successfully applied and resulted in sustained increases in BDNF mRNA and protein levels (Lauterborn et al., 2003) . Thus, future studies will assess the effects of similar protocols on AMPAr expression, PDZ protein degradation, and calpain activation.
Consistent with the protein data, prolonged exposure to CX614 also affected AMPAr gene expression and reduced their mRNA levels. The loss of GluR mRNA expression occurred within all principal cell layers of hippocampus with 48-h CX614 treatment. Although the combination of AP-5 and CNQX significantly inhibited CX614-induced decreases in total hippocampal AMPAr protein levels, these blockers did not equally inhibit the decrease in GluR mRNA levels between regions CA3 and CA1. AP-5 and CNQX cotreatment blocked the reduction in GluR mRNA levels in CA3, but it was ineffective in CA1. One explanation for this regional disparity may be due to developmental differences in AMPA receptor antagonist binding between the CA3 and CA1 subfields. During postnatal development, [
3 H]CNQX binding attains adult levels in CA3 by postnatal day 15, whereas in CA1 it is not attained until postnatal day 40 (Standley et al., 1995) . Given that the present study utilized slice cultures that at the time of drug treatment approximated postnatal day 20 animals, the deficiency in CA1 [
3 H]CNQX binding may account for the regional difference in the blocking effect observed here. Alternatively, the differential effects of the combination CNQX and AP-5 on CX614-induced decreases in GluR mRNA levels between the hippocampal subfield might reflect greater spontaneous release of glutamate in CA1 than in CA3.
Overall, the main findings suggest that several factors can contribute to CX614-induced down-regulation of AMPAr. First, enhancing AMPAr activity is a major mechanism underlying AMPAr down-regulation; it involves activity-dependent, calpain-mediated degradation of spectrin and AMPArinteracting PDZ proteins, which would be expected to interfere with receptor stabilization and trafficking. A second mechanism of AMPAr down-regulation involves calpain-independent decrease of the transcription of the genes coding for these subunits, at least in CA1. Future studies should assess whether other manipulations, which increase synaptic activity in cultured slices (e.g., treatment with functionally distinct ampakines, inhibition of GABAergic transmission), have similar or differential effects on levels of PDZ proteins and AMPAr to those observed here.
In conclusion, this study further implicates calpain in physiological activity-induced changes in postsynaptic structures in the absence of cell toxicity and demonstrates that with prolonged enhancement of glutamatergic synaptic activity, AMPAr loss 1) is mediated by increased AMPAr activation, 2) involves calpain-dependent proteolysis of SAP97 and GRIP1, 3) is reflected at the mRNA level by suppression of AMPAr gene expression, and 4) is not associated with cell damage.
